Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 239 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Buffered Saline Clear all

Conditions: Atopic Dermatitis
Interventions: GBR 830, Placebo; Biological
Lead sponsor: Ichnos Sciences SA; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Rogers, Arkansas • Los Angeles, California • San Diego, California + 9 more

Conditions: Malaria, Malaria,Falciparum
Interventions: PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline; Biological · Other
Lead sponsor: Sanaria Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
Interventions: Ficlatuzumab, Cetuximab; Drug
Lead sponsor: James J Lee; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteoarthritis of the Knee
Interventions: 1.2% Sodium Hyaluronate, Buffered Saline; Device
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 34
States / cities: Homewood, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 30 more

Conditions: Trauma, Vascular System Injury
Interventions: Acellular Tissue Engineered Vessel (ATEV); Biological
Lead sponsor: Humacyte, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 27
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 18 more

Conditions: Stroke, Stroke, Acute, Stroke, Ischemic
Interventions: AER-271, Placebo; Drug
Lead sponsor: Aeromics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dermatitis
Interventions: Artificial Fecal Insult, Phosphate Buffered Saline; Other
Lead sponsor: Kimberly-Clark Corporation; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Irving, Texas

Conditions: Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma, Anaplastic Astrocytoma
Interventions: Dendritic Cells, Imiquimod; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prosthetic-joint Infection
Interventions: Surgiphor Irrigation Solution, Sterile saline; Device
Lead sponsor: Center for Innovation and Research Organization; Network
Eligibility: 18 Years and older
Enrollment: 868 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Baltimore, Maryland • Columbia, Missouri + 1 more

Conditions: Dengue
Interventions: Placebo (SC), Placebo (ID), Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: VCL-IPM1, VCL-IPT1, PBS; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Stony Brook, New York

Conditions: Healthy
Interventions: ExPEC4V (4 : 4 : 4 : 4), ExPEC4V (4 : 4 : 4 : 8), ExPEC4V (8 : 8 : 8 : 8), ExPEC4V (8 : 8 : 8 : 16), ExPEC4V (16 : 16 : 16 : 16), Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 848 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: Mesa, Arizona • Hollywood, Florida • Leesburg, Florida + 14 more

Conditions: HIV-1-infection
Interventions: 3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 45 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Seattle, Washington

Conditions: Hypertension, Portal
Interventions: GR-MD-02, Placebo; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 46
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 39 more

Conditions: Cytomegalovirus Infections, HIV Infections, Vaccine
Interventions: CMV-MVA Triplex, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more

Conditions: Covid19
Interventions: Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo; Biological
Lead sponsor: KBio Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: West Palm Beach, Florida • Meridian, Idaho • Winston-Salem, North Carolina + 3 more

Conditions: Shigellosis
Interventions: Shigella4V2, Placebo; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio

Conditions: Plague
Interventions: Flagellin/F1/V, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer Disease
Interventions: ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 27
States / cities: Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more

Conditions: Coronavirus Disease 2019
Interventions: Placebo, Leronlimab (700mg); Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 50 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more

Conditions: Bone Loss
Interventions: Amount of PDGF-BB in PRF preparation vs. GEM21, Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation, Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes, Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Knee Osteoarthritis
Interventions: Durolane, PBS; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 25
States / cities: Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more

Conditions: Anemia, Sickle Cell
Interventions: Rivipansel, Placebo; Drug · Other
Lead sponsor: Biossil Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 126
States / cities: Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more

Search by objective public record fields.

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee

Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma

Phase 1 Study to Assess AER-271

Infant Fecal Insult Study

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

Surgiphor vs Saline Joints

Tetravalent Chimeric Dengue Vaccine Trial

Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

2013/2017 H7N9 Prime-Boost Interval

Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis

Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease